Raynal C, Corvol H
CHU de Montpellier, Laboratoire de Gé né tique Molé culaire Montpellier, France; Université de Montpellier, EA7402, Montpellier, France.
Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, CRSA, Paris, France; AP-HP, Hôpital Trousseau, Service de Pneumologie Pédiatrique, Paris, France.
Arch Pediatr. 2020 Feb;27 Suppl 1:eS13-eS18. doi: 10.1016/S0929-693X(20)30045-2.
Because CFTR gene studies now represent one of the most frequent genetic analyses routinely performed worldwide, the number of rare CFTR variants identified in various clinical situations, regularly increases. To provide appropriate diagnosis and prognosis to CF patients as well as appropriate genetic counseling to families, the clinical impact and the phenotypic spectrum of variants identified by diagnostic techniques need to be characterized. Three complementary locus specific databases, called CFTR1, CFTR2 and CFTR-France were developed to address these issues. Besides, the growing knowledge of the CF pathophysiology and the technical evolution in molecular biology allowed to identify candidate modifier genes, regulatory loci, epigenetic profiles and trans-regulators that could help to refine genotype-phenotype correlations at the individual level. These different factors may contribute to the large phenotypic variability between patients with CF, even when they carry identical CFTR variants, regarding lung function, meconium ileus susceptibility or the risk for developing CFTR-related diabetes and liver disease. Finally, the availability of new therapies that target the CFTR protein for numbers of CF patients led to the identification of 'good' and 'poor' responders, thus raising questions of pharmacogenetics factors that may influence treatment efficiency as a novel feature of the complexity of CF patients' management. © 2020 French Society of Pediatrics. Published by Elsevier Masson SAS. All rights reserved.
由于CFTR基因研究目前是全球常规开展的最常见的基因分析之一,在各种临床情况下鉴定出的罕见CFTR变异数量不断增加。为了给囊性纤维化(CF)患者提供恰当的诊断和预后评估,并为其家庭提供合适的遗传咨询,需要对诊断技术鉴定出的变异的临床影响和表型谱进行特征描述。为此开发了三个互补的位点特异性数据库,分别称为CFTR1、CFTR2和CFTR-法国。此外,对CF病理生理学的认识不断增加以及分子生物学技术的发展,使得能够鉴定出可能有助于在个体水平细化基因型-表型相关性的候选修饰基因、调控位点、表观遗传谱和反式调节因子。这些不同因素可能导致CF患者之间出现很大的表型变异性,即使他们携带相同的CFTR变异,在肺功能、胎粪性肠梗阻易感性或发生CFTR相关糖尿病和肝病的风险方面也是如此。最后,针对许多CF患者的靶向CFTR蛋白的新疗法的出现,导致了“良好”和“不良”反应者的鉴定,从而引发了关于可能影响治疗效果的药物遗传学因素的问题,这是CF患者管理复杂性的一个新特征。© 2020法国儿科学会。由爱思唯尔马松出版社出版。保留所有权利。